Top entities: ADC Therapeutics, Pomerantz LLP, Loncastuximab tesirine, Danielle Peyton.

What category does this event fall under?

Regulatory — classified as securities fraud investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Pomerantz LLP investigates claims ADC Therapeutics · ADC Therapeutics fell · ADC Therapeutics announced data

Is this event still developing?

This is an active story, last updated Jun 28, 2026. Coverage continues to evolve.

Regulatory securities fraud investigation

ADC Therapeutics faces fraud investigation

Q: When did this event occur?

First reported Jun 11, 2026; last updated Jun 28, 2026.

Q: What is the market impact?

General. The market is negatively impacted by the significant drop in ADC Therapeutics' stock price, reflecting investor concern over the efficacy and safety of Loncastuximab tesirine.

Analysis based on 7 articles · First reported Jun 11, 2026 · Last updated Jun 28, 2026

Sentiment

-70

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the significant drop in ADC Therapeutics' stock price, reflecting investor concern over the efficacy and safety of Loncastuximab tesirine. This event highlights the risks associated with pharmaceutical trials and potential securities fraud, leading to increased scrutiny on similar companies in the biotechnology sector.

pharmaceuticals legal services

Event Summary

Pomerantz LLP is investigating ADC Therapeutics for securities fraud following a substantial drop in its stock price. This decline occurred after ADC Therapeutics announced disappointing topline data from its Phase 3 LOTIS-5 trial for Loncastuximab tesirine, which showed a higher death rate in the Loncastuximab tesirine arm compared to the immunotherapy arm, despite extending progression-free survival by 1.4 months. The stock fell by 66.56% over two trading sessions, prompting the law firm to investigate whether ADC Therapeutics and its officers engaged in unlawful business practices.

Key Actions

100 Pomerantz LLP investigates claims ADC Therapeutics

95 ADC Therapeutics fell

90 ADC Therapeutics announced data

Entities Involved

stock

ADC Therapeutics

ADC Therapeutics is facing a securities fraud investigation by Pomerantz LLP after its stock price plummeted due to disappointing Phase 3 trial results for Loncastuximab tesirine.

Importance 100.0 Sentiment -80.0

priv

Pomerantz LLP

Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud on behalf of investors, aiming to recover damages for class members.

Importance 80.0 Sentiment 60.0

oth

Loncastuximab tesirine

Loncastuximab tesirine, a drug developed by ADC Therapeutics, showed disappointing results in its Phase 3 LOTIS-5 trial, leading to a significant drop in ADC Therapeutics' stock price and a securities fraud investigation.

Importance 70.0 Sentiment -70.0

per

Danielle Peyton

Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the class action against ADC Therapeutics.

Importance 30.0 Sentiment 0.0

Relationships

Pomerantz LLP related ↔ Danielle Peyton

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard